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Abstract In patients with leukemia, the portal(s) and rea-
sons for the persistence of an Escherichia coli recurrent
bacteremia remain unclear. Adult Hematology Clinic
(AHC) databases at the State Clinical Hospital in Gdańsk
were reviewed to evaluate the frequency of E. coli bacter-
emia between 2002 and 2005. Blood and bowel E. coli
strains were obtained and the genetic relatedness of the
strains was analyzed. The rate of E. coli bacteremia per
1,000 admissions at the AHC was higher (85.0) than in the
other clinics of the hospital (2.9), p<0.001. A higher mor-
tality was observed in patients with a history of E. coli
versus non-E. coli bacteremia [30/95 (31 %) vs. 53/430
(12 %), p<0.001]; 72.8 % of patients with leukemia had
an unknown source of bacteremia. In 2005, 6 out of 25
(24 %) patients with leukemia had ≥2 episodes of E. coli-
positive blood cultures. These gastrointestinal E. coli iso-
lates were replaced within 3–8 weeks with a new E. coli H
genotype. A recurrent episode of bacteremia was usually
caused by an infection with a transient E. coli H genotype
identical to that found in the subject’s bowel. Consistent
with the definition of bowel/blood translocation, the bowel
appeared to be a portal for E. coli in these subjects and,
hence, a clear source for their recurring bacteremia.
Introduction
While the presence of a hematologic malignancy has been
considered a risk for recurrent vancomycin-resistant Entero-
coccus (VRE) bacteremia, the recurrence of Escherichia coli
bacteremia in patients with leukemia has not been well
studied [1–3]. Although E. coli is recognized as an impor-
tant pathogen in recurrent bacteremia, patients who have a
bacteremia caused by a Gram-negative organism reportedly
have a relatively low risk (6 %) of recurrent episodes [2–9].
In patients with a hematologic malignancy and recurrent
bacteremia, VRE colonize the gastrointestinal tract and of-
ten persist in the colon for several months [1]. Despite
clinical and laboratory examination, in leukemia, the source
or portal of infection in those patients with recurrent bacter-
emia often remains unknown. Further, we lack data on the
short- versus long-term E. coli colonization of the bowel and
the associated risk of recurrent bacteremia. Several factors
may contribute to the risk of recurrent bacteremia. First, E.
coli may remain viable in the hospital environment for
several months [10–18]. Susceptible patients such as those
who have leukemia may be at risk for recurrent infection
with a E. coli strain(s) that persists in such a hospital
environment. Based on current trends, the risk of recurrent
E. coli bacteremia, although low, may also increase due to
the increasing prevalence of an “alarm” antibiotic-resistant
E. coli [10]. Other factors that may increase the risk of E.
coli bacteremia are frequent hospitalizations and the longer
survival of patients with leukemia. Because the frequency of
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E. coli recurrent bacteremia is reportedly low, the risk of
mortality in patients with recurrent E. coli versus non-E. coli
bacteremia is under-investigated and remains unclear. In this
study on E. coli bacteremia, we determined the source/portal
of recurrent infection, the mortality incidence in those with a
history of E. coli versus non-E. coli bacteremia, and the
similarity of E. coli genotypes in blood and bowel over time.
This aimed to define whether a recurrence of bacteremia
was caused by the same genotype persisting in the bowel as
a pathogen or if the recurrence was caused by a transient
new colonizer. Here, we report that recurrent E. coli bacter-
emia was a frequent event in leukemic malignancy and was
accompanied by an increased risk of mortality. Recurrent
bacteremia was not caused by persistent colonizers: blood
re-infections mostly occurred with a new E. coli genotype
that was also temporarily present in the bowel, suggesting
that the bowel was the source of the translocating pathogen.
Materials and methods
Patients and collection of samples
The analysis was focused on the Independent State Clinical
Hospital at Gdańsk University of Medicine (State Hospital),
with a total number of 1,265 hospital beds and 34 subspecialty
clinics and/or wards, including an Adult Hematology Clinic
(AHC). The databases in the State Hospital and the microbi-
ology laboratory were reviewed to identify those patients who
had Gram-negative bacteremia between January 1, 2002 and
December 31, 2005. All patients with recurrent episodes [at
least two episodes that occurred 30 days apart or also occa-
sionally shorter intervals (see results for patient P1) with blood
culture results negative in the interim] were identified. In
addition, all E. coli cultures obtained from blood and stool
samples from 25 patients with leukemia (collected during the
period 2004–2005 at the AHC) were saved and stored
at −80 °C. A single bacteremic episode was defined by pos-
itive blood cultures performed on a single patient within a 7-
day period. Polymicrobial bacteremia was considered to be
Gram-negative if at least one Gram-negative organism
was isolated in the blood culture. Bacteremic episodes
with onset >48 h after admission were considered to be
nosocomial. A recurrence of bacteremia was defined as
a second episode of bacteremia during the study period
that was caused by the same Gram-negative species. A
relapse was defined as a recurrence of bacteremia
caused by the same strain that caused the initial infec-
tion. A re-infection was defined as a recurrence of
bacteremia caused by a different strain than the one that
caused the initial infection [>3 bands difference in
pulsed-field gel electrophoresis (PFGE) or coefficient of sim-
ilarity <90 %] [19]. Bacteremia was considered to be due to a
gastrointestinal tract translocation when: (a) an isolate with the
same DNA fingerprint as the blood isolate was obtained from
a stool specimen (>108 CFU/g of feces); (b) no alternative
primary site of infection was detected; (c) urine culture results
were negative [<1,000 colony-forming units (CFU)/mL]; and
(d) no acquired digestive tract abnormalities were present
[20].
Genotyping by PCR MP and REA-PFGE
Frozen isolates were thawed and cultured on trypticase soy
agar with 5 % sheep blood agar (Becton Dickinson) and
incubated at 37 °C for 24 h. Species identification was done
with a Vitek identification card (bioMérieux Vitek). The
polymerase chain reaction melting profiles (PCR MP) pro-
cedure was carried out according to the method described
for E. coli isolates [21]. This method allows specific gradual
amplification of genomic DNA in terms of thermal stability
starting from less stable DNA fragments amplified at lower
Td values to more stable ones amplified at higher Td values.
This feature may be used to obtain sets of electrophoretic
patterns of DNA fragments amplified during ligation-
mediated (LM) PCR performed at various denaturation tem-
peratures. A low Td during LM PCR leads to limited and
specific amplification of a small number of DNA fragments
characteristic for the bacterial strain. Restriction endonucle-
ase analysis (REA)-PFGE was performed with restriction
digestion of the chromosomal DNA with 20 U of XbaI
(Sigma) and with the FIGE Mapper Electrophoresis System
(Bio-Rad), according to a method described previously [21].
Statistical analysis
Data were statistically analyzed using the Microsoft Excel
2007 program. Categorical variables were compared using
Chi-square analysis. p-values less than 0.05 were considered
to be significant.
Results
Bacteremia at the Independent State Clinical Hospital,
years 2002–2005
The hospital’s and microbiology laboratory’s databases be-
tween 2002 and 2005 included records for 152,388 patients
admitted, including 2,741 patients admitted to the AHC.
While the frequency of bacteremia among all the admitted
patients to the State Hospital was 1.6 %, the patient popu-
lation in the AHC had a significantly higher bacteremia rate
of 19.1 % (p<0.001) (Table 1). The observed difference in
the frequency of bacteremia in those subjects in the general
population of the State Hospital versus those in the AHC
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was also calculated as the rates in blood cultures per 1,000
admissions. While, overall, the State Hospital rate was 57.4
per 1,000, it was dramatically higher for the AHC
(1,235/1,000) and significantly lower for the remaining
State Hospital clinics (35.8/1,000).
In order to understand the increased frequency of bacter-
emia in the AHC, the analysis was focused on Gram-negative
microorganisms. We revealed that Enterobacteriaceae were
more frequently isolated in the AHC ward. While the State
Hospital rate of Gram-negative bacteremia was low (10.4 per
1,000), the rate was significantly higher for AHC subjects
(193.7 per 1,000). Among the Enterobacteriaceae, the most
frequently isolated was E. coli; rates of 85.0 and 2.9 per 1,000
for the AHC and the remaining State Hospital clinics, respec-
tively, were noted. The State Hospital records identified a total
of 652 episodes of E. coli bacteremia, of which 223 occurred
in 95 AHC patients. This suggested the occurrence of multiple
bacteremic episodes and/or recurrent E. coli bacteremia in
some patients (Table 1).
Recurrence or persistence of bacteremia may be a result of
a therapeutic failure due to the presence of so called “alarm”
microorganisms that are resistant to multiple antibiotics. Be-
tween 2002 and 2005, there were only 40 bacteremias of
extended-spectrum beta-lactamase (ESBL)E. coli in the entire
State Hospital, and half of these cases were from the AHC.
These data suggest that antibiotic resistance was less likely to
be a primary factor in the recurrence of E. coli bacteremia.
To understand the underlying cause(s) of the increased
frequency of bacteremia at the AHC, we performed an anal-
ysis of the identified sources/portals of infection (Table 2).
While an extra-intestinal source of bacteremia was found in
the majority of clinics, in the AHC, only 27.4 % of cases had
this as an identified source. The most frequent portal of E. coli
bacteremia was the urogenital tract. However, while a urogen-
ital source of E. coli accounted for 16.8 % of bacteremia for
AHC patients, this number was 83.8 % in Internal Medicine
and 39.3 % in Surgery. These data are consistent with our
hypothesis that, in roughly 72.6 % of AHC patients (Table 2)
with an unknown E. coli portal, the bowel was the likely
source of their infection.
As the frequency of E. coli bacteremia was higher in the
AHC ward (which serves a patient population with
leukemia/lymphoma), we focused our further analyses on
these patients (Table 3). The highest rate of E. coli bacteremia
was observed in patients with myeloid leukemia, lymphoblas-
tic leukemia, and Hodgkin’s lymphoma (22.2 %, 20.4 %, and
27.3 %, respectively), while lower rates were observed in
patients with multiple myeloma and immunocytoma (11.7 %
Table 1 State Hospital admissions, number of blood cultures, and Escherichia coli bacteremias in the years 2002–2005
AHC Other clinics Total p* AHC vs. other
Number of patients hospitalized 2,741 149,647 152,388 –
Number (%) of patients with positive blood cultures 525 (19.1 %) 1,974 (1.3 %) 2,499 (1.6 %) <0.001
Number of positive blood cultures/rate per 1,000 admissions 3,387/1,235.7 5,359/35.8 8,746/57.4 <0.001
Number of Enterobacteriaceae isolates/rate per 1,000 admissions 531/193.7 1,053/7.0 1,584/10.4 <0.001
Number of E. coli strains/rate per 1,000 admissions 233/85.0 431/2.9 664/4.4 <0.001
Number of unique patients/cases of bacteremia with presence of
E. coli
95/223 235/429 330/652 –
Number (%) of ESBL E. coli 20 (0.53 %) 20 (0.33 %) 40 (0.41 %) 0.008
*p < 0.05 was considered to be significant









Patients, n/% Patients, n/% Patients, n/% Patients, n/% Patients, n/% Patients, n/%
Total 95 149 39 30 12 23
Known 26/27.4 % 148/99.3 % 37/94.9 % 30/100.0 % 9/75.0 % 23/100.0 %
Urogenital tract 16/16.8 % 125/83.8 % 13/39.3 % 7/38.8 % 3/25.0 % 4/17.3 %
Vascular catheters 1/1.0 % 3/2.0 % 3/9.0 % 0/0.0 % 5/41.6 % 4/17.3 %
Respiratory tract 5/5.2 % 10/6.7 % 5/15.1 % 13/72.2 % 0/0.0 % 15/65.2 %
Wound 4/4.2 % 10/6.7 % 16/48.4 % 10/55.5 % 1/8.3 % 0/0.0 %
Unknown 69/72.6 % 1/0.7 % 2/5.1 % 0/0.0 % 3/25.0 % 0/0.0 %
Eur J Clin Microbiol Infect Dis (2013) 32:1393–1400 1395
and 14.5 %, respectively). E. coli monobacteremia represent-
ed 20.7 to 22.7 % of all E. coli-infected blood cultures in
patients with leukemia and lymphoma, and 9.3 % to 12.3 % in
multiple myeloma and immunocytoma.
Because the frequency of E. coli recurrent bacteremia is
reportedly low, the risk of mortality in patients with recurrent
E. coli versus non-E. coli bacteremia is under-investigated and
remains unclear. Table 4 summarizes data on the number of
AHC patients who died, relative to their history of E. coli
bacteremia. Out of 525 patients with a history of bacteremia,
83 (15.8 %) patients died due to the bacteremia itself. Out of
95 patients with a history of E. coli bacteremia, 30 (31 %)
patients died. In contrast, out of 430 patients with a history of
bacteremia caused by pathogens other than E. coli, 53 (12 %)
patients died. The number of deaths connected to their basic
diseases was similar for those with or without a history of E.
coli bacteremia (p=0.134). These results suggest that a history
of E. coli bacteremia, per se, was associated with increased
risk of mortality (p<0.001).
Genetic typing for the characterization of E. coli isolates
from patients with leukemia/lymphoma and recurrent
bacteremia
Since we postulated that the source/portal of recurrent infec-
tion would be the bowel, we focused on the similarity of E.
coli genotypes in blood and bowel isolates over time. To
define whether a recurrence of bacteremia was caused by the
same genotype persisting in the bowel as a pathogen (or if the
re-infection was caused by a transient new colonizer), we first
characterized E. coli DNA fingerprint patterns produced by
PCR MP and REA-PFGE. DNA fingerprinting of 65 E. coli
isolates from blood and/or bowel identified 32 genotype pat-
terns, which were named H1 to H32 (Fig. 1, representative
results by using the PCR MP method). Among the most
frequent genotypes, the H2 pattern was represented in nine
E. coli isolates, H17 and H22 were represented in six isolates
each, and the remaining H types were restricted to one or two
E. coli isolates (Table 5). E. coli genotype H2, which repre-
sented a nosocomial strain, was identified in the blood cultures
of four patients with leukemia. The other frequent genotype
(E. coliH22) was isolated from the blood of two patients (P10
and P18). Among the genotypes that were less frequent, E.
coli H9, H11, H13, H15, H16, H20m and H30 were isolated
from both the blood and the bowel samples (one patient for
each genotype), which is consistent with an E. coli isolate H
fingerprint specificity.
Recurrent E. coli bacteremia was associated
with re-infection by different E. coli H genotypes
Among the 25 patients with leukemia/lymphoma hospitalized
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and P25) had two or more episodes of positive E. coli blood
cultures. In patient P9, we identified two episodes of bacter-
emia, each caused by a different E. coli H genotype (H20 and
H23, respectively). Patient P11 developed two episodes of E.
coli bacteremia including genotypes H28 or H29.
Correlation between the presence E. coli H genotypes
in the bowel and blood cultures
Figure 2 presents examples of E. coli H fingerprints showing
identical DNA patterns of isolates from the bowel and the blood.
For example, patient P5 had a blood and bowel culture positive
for E. coli H11. Patient P1 showed several episodes of bacter-
emia and identical blood and bowel E. coli, suggesting that a
different E. coli inhabitant of the bowel translocated to the
bloodstream. Patient P1 was hospitalized six times between
September 9th 2004 and September 30, 2005, and spent a total
of 236 days in the hospital due to a recurrent E. coli bacteremia
with multiple E. coli isolates/H fingerprints, with identical E. coli
isolates/H fingerprints identified in the bowel and with no evi-
dence of another obvious source of infection (Table 5). Five
blood cultures obtained within the above-mentioned period were
positive forE. coli.E. coli isolated from blood and stool (cultures
done on same day, May 10th) showed an identical H16 geno-
type. Following episodes of bacteremia (May 22nd, 25th, and
27th, and August 7th) were caused by an ESBL E. coli H17
genotype. This E. coli H17 was isolated from the patient’s urine
on June 20th and from his stool on August 7th. Following bone
marrow transplant, the patient received ciprofloxacin, and begin-
ning May 9th, he was treated with piperacillin, tazobactam, and
amikacin. Once a positive result of ESBL E. coli isolated from
blood was obtained, an additional antibiotic (meropenem) was
added to the therapeutic strategy and continued until July 6th,
2005. Thus, in our select patient, the E. coli H genotype that
caused bacteremia was eliminated from the vascular bed follow-
ing antibiotic treatment. After an asymptomatic period, the infec-
tion was replaced with another rare E. coli H genotype identical
to that identified in the bowel at the time. In agreement with the
established bacteriologic and DNA fingerprinting criteria for
translocation, in the absence of an alternative source of infection
in these patients, recurrent E. coli bacteremia resulted from E.
coli translocation from the bowel to the bloodstream.
Discussion
Septicemia and/or bacteremia is the 13th leading cause of
death in the United States, and the age-adjusted mortality rate
associated with sepsis has increased over the last five decades
[2, 3]. In the United States, about 500,000 cases of sepsis
occur each year, one-fourth of which are associated with
Gram-negative bacteremia [4]. Gram-negative bacteremia is
a serious infection, for which the estimated crude mortality
rate is 20–50% [5]. It is estimated that 6–10% of patients who
have an episode of Gram-negative bacteremia will have one
recurrent episode [6–9]. E. coliwas reported as only the fourth
most common cause of nosocomial bacteremias [10–16, 22].
In present study, we report that, unexpectedly, recurrent E.
coli bacteremia was a frequent event in leukemic malignancy,
and that blood re-infection usually occurred with a new E. coli
DNA H genotype present in the bowel. We observed that the
recurrent E. coli bacteremia in these leukemic patients was
Table 4 Mortality of patients hospitalized in the AHC in the years 2002–2005
Patients with history of
E. coli bacteremia
Patients without history of
E. coli bacteremia
Total p-Value
Number of patients with positive blood cultures 95 430 525 –
Number of patients who did not die during hospitalization 38 289 327 0.002
Number of patients who died due to basic disease 27 88 115 0.134
Number of patients who died due to bacteremia 30 53 83 <0.001
Fig. 1 Polymerase chain reaction melting profiles (PCR MP) finger-
prints for representative Escherichia coli isolates from patients of the
Adult Hematology Clinic (AHC) ward showing H genotypes from H1
to H20. PCRMP fingerprinting H types are given above each lane. The
DNA amplicons were electrophoresed on 6 % polyacrylamide gels
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Table 5 Patients’ clinical histories and results of the genotyping of E. coli isolates
Clinical recognition Patient Isolate Date of isolation (day.-mo.-yr) Specimen source Genotype
Myeloid leukemia P1 1 23-09-2004 Blood H1
2 05-02-2005 Blood H7
3 05-02-2005 Blood H8
4 05-02-2005 Blood H9
5 07-02-2005 Stool H9
6 07-02-2005 Stool H10
7 10-05-2005 Blood H16
8 10-05-2005 Stool H16
9 19-05-2005 Blood H16
10 19-05-2005 Blood H16
11 22-05-2005 Blood H17
12 22-05-2005 Blood H17
13 25-05-2005 Blood H17
14 25-05-2005 Blood H17
15 27-05-2005 Blood H17
16 08-07-2005 Blood H17
P2 17 22-10-2004 Blood H4
P3 18 22-10-2004 Blood H2
P4 19 24-11-2004 Blood H2
P5 20 15-02-2005 Blood H11
21 15-02-2005 Blood H11
22 18-02-2005 Stool H11
23 18-02-2005 Stool H12
24 18-02-2005 Stool H11
25 18-02-2005 Stool H12
P6 26 22-02-2005 Blood H13
27 25-02-2005 Stool H13
P7 28 05-03-2005 Blood H14
P8 29 28-04-2005 Blood H15
30 28-04-2005 Stool H15
P9 31 28-07-2005 Blood H20
32 01-08-2005 Stool H20
33 30-09-2005 Blood H23
34 30-09-2005 Blood H23
P10 35 16-08-2005 Blood H22
36 16-08-2005 Blood H22
37 16-08-2005 Stool H22
P11 38 31-09-2005 Blood H25
39 04-11-2005 Blood H28
40 04-11-2005 Blood H29
P12 41 29-11-2005 Blood H31
P13 42 05-12-2005 Blood H32
Lymphoblastic leukemia P14 43 16-11-2004 Blood H5
P15 44 13-09-2004 Blood H2
45 12-10-2004 Blood H2
P16 46 17-06-2005 Blood H19
P17 47 29-07-2005 Blood H21
48 29-07-2005 Blood H21
P18 49 30-08-2005 Blood H22
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caused either by hospital strains (e.g., E. coli genotype H2) or
by multiple, rare H genotypes, each representing a different E.
coli strain of unknown origin. On multiple occasions, we
found different E. coli H genotypes in blood samples isolated
during consecutive episodes of bacteremia, despite an effec-
tive therapy following the initial infection. The lack of an
identified focus of infection suggested that, after the elimina-
tion of E. coli from the bloodstream, another transient bowel
inhabitant disseminated to the vascular bed. To our knowl-
edge, the current clinical literature describes only one study
including evidence of direct translocations of E. coli from the
bowel to the circulation and which involves newborns with
urinary tract infections [20].
A study of VRE bacteremia concluded that recurrent VRE
bacteremia was uncommon, and that recurrent episodes were
separated by 3 months and were caused by identical or related
VRE strains [1]. Our study showed that E. coli which were
resident in the bowel of a patient with leukemia were much less
stable and the dominant genotype changed over a period of a
few weeks. Thus, in contrast to an expected persistent several
months colonization with the same strain, we observed that
episodes of recurrent bacteremia represented independent re-
infection events originating from the re-established new bowel
E. coli isolates. Re-infection with E. coli is consistent with a
study by Johnson et al. [23], who examinedE. coli isolates from
35 children with recurrent urinary tract infection (UTI). Five of
the nine patients were re-infected with new strains. We hypoth-
esize that antibiotic therapy destabilized the normal intestinal
flora and increased the risk for re-colonization with potentially
pathogenic transient E. coli colonizers.
The exact mechanism of translocation of indigenous bac-
teria from the gut is not known but may involve the over-
growth of intestinal bacteria, a deficiency in the host’s
immune defenses, and/or damage to the intestinal mucosal
barrier [24]. The possibility exists that immunosuppressive
therapy resulting in the dysfunction of white cells or the
invasive capacity of some E. coli allow the translocation of
E. coli to the mesenteric circulation [24–29].
Table 5 (continued)
Clinical recognition Patient Isolate Date of isolation (day.-mo.-yr) Specimen source Genotype
50 30-08-2005 Stool H22
51 05-09-2005 Stool H22
P19 52 02-11-2005 Blood H26
P20 53 04-11-2005 Blood H27
P21 54 06-11-2005 Blood H30
55 06-11-2005 Stool H30
Hodgkin’s lymphoma P22 56 06-10-2004 Blood H3
P23 57 26-11-2004 Blood H2
58 28-11-2004 Stool H2
59 29-11-2004 Stool H2
60 15-03-2005 Stool H2
61 18-03-2005 Blood H2
P24 62 27-01-2005 Blood H6
P25 63 06-07-2005 Blood H18
64 23-10-2005 Blood H24
65 23-10-2005 Blood H24
Fig. 2 Representative results of monitoring the spread of bacteria within
patients by using the PCR MP technique. The isolates shown represent
three patients: genotype H11 from patient P5, genotype H20 from patient
P9, and genotype H22 from patient P18. Lanes marked by numbers
indicate the number of the isolate shown in Table 5. Lanes marked by
B and S contain strains isolated from blood and stool, respectively. The
DNA amplicons were electrophoresed on 6 % polyacrylamide gels
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The detection of frequent recurrent E. coli bacteremia
suggests the need for a careful patient evaluation, as the risk
of mortality is potentially higher compared to those with a
history of non-E. coli bacteremia. Our data suggest that
standards for the prevention of recurrent bacteremia should
be re-evaluated. Clinical trials might include novel regimens
for selective decontamination to eradicate the transient E.
coli H genotypes from the gut and, therefore, reduce the risk
for recurrent bacteremia [30].
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